BIJUVA
Peakestradiol and progesterone
NDAORALCAPSULE
Approved
Oct 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
6/8 — Strong
BIJUVA (estradiol and progesterone) is estrogen receptor agonists [moa]. First approved in 2018.
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BIJUVA is an oral capsule combining estradiol and progesterone, indicated for menopausal hormone therapy. It works as an estrogen receptor agonist to address vasomotor symptoms and related conditions in postmenopausal women. The fixed-dose combination aims to provide balanced hormone replacement with a simplified dosing regimen.
$0.621MPart D
Peak6.5 years to LOEProduct is at peak lifecycle stage with modest Part D penetration; commercial team size likely stable with focus on market maintenance and patient retention.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition
Started Apr 2011
3 enrolled
HyperandrogenemiaPolycystic Ovary Syndrome
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Started Feb 2009
25 enrolled
Polycystic Ovary SyndromeHyperandrogenism
Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Started Sep 2006
4 enrolled
Polycystic Ovary SyndromeHyperandrogenism
Assessment of the Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition
Started Apr 2000
60 enrolled
HyperandrogenemiaPolycystic Ovary Syndrome (PCOS)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.